Argos Therapeutics, Inc. (NASDAQ:ARGS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “

Several other brokerages have also commented on ARGS. Stifel Nicolaus dropped their price target on shares of Argos Therapeutics to $1.20 and set a “hold” rating for the company in a research report on Friday, March 17th. FBR & Co dropped their price target on shares of Argos Therapeutics from $2.00 to $1.20 and set a “mkt perform” rating for the company in a research report on Wednesday, April 19th. Four analysts have rated the stock with a hold rating, Argos Therapeutics has an average rating of “Hold” and a consensus target price of $3.23.

Argos Therapeutics (NASDAQ:ARGS) traded up 0.0294% during mid-day trading on Tuesday, reaching $0.3400. 971,774 shares of the company traded hands. The stock’s market capitalization is $14.06 million. The stock has a 50-day moving average of $0.42 and a 200 day moving average of $2.09. Argos Therapeutics has a 52-week low of $0.31 and a 52-week high of $7.08.

ILLEGAL ACTIVITY WARNING: “Argos Therapeutics, Inc. (ARGS) Rating Increased to Hold at Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/07/11/argos-therapeutics-inc-args-rating-increased-to-hold-at-zacks-investment-research.html.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get a free copy of the Zacks research report on Argos Therapeutics (ARGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.